CD44 and esophageal squamous cell carcinoma: However, ZSH‐2208 significantly reduced the gene expression levels of CD44, a recognised stemness marker in ESCC‐TRCs, which suggest that ZSH‐2208 may exhibit enhanced efficacy against CSCs.